WHO warns of spread of cholera outbreak from Sudan to Chad refugee camps
By Emma Farge
GENEVA (Reuters) -The World Health Organization warned on Friday that cholera cases in Sudan are set to rise and could spread to neighbouring countries, including Chad, which hosts hundreds of thousands of refugees from Sudan's civil war in crowded conditions.
The more than two-year-old war between the Sudanese army - which took full control of Khartoum state this week - and the paramilitary Rapid Support Forces has spread hunger and disease and destroyed most health facilities. Drone attacks in recent weeks have interrupted electricity and water supplies in the capital Khartoum, driving up cases there.
"Our concern is that cholera is spreading," Dr Shible Sahbani, WHO Representative for Sudan, told reporters in Geneva by video link from Port Sudan.
He said that cholera had reached 13 states in Sudan, including North and South Darfur which border Chad, and that 1,854 people had already died in the latest wave as the dangerous, rainy season sets in.
"We assume that if we don't invest in the prevention measures, in surveillance, in the early warning system, in vaccination and in educating the population, for sure, the neighbouring countries, but not only that, it can maybe spread to the sub-region," he said.
He called for humanitarian corridors and temporary ceasefires to allow mass vaccination campaigns against cholera and other disease outbreaks such as Dengue fever and malaria.
Cholera, a severe, potentially fatal diarrhoeal disease, spreads quickly when sewage and drinking water are not treated adequately.
Sahbani said that this posed a high risk for Sudanese refugees, including some who had survived attacks on a displacement camp in Darfur, and who are living in cramped, makeshift border sites on the Chadian side of the border.
"In overcrowded, unsanitary conditions, a potential outbreak could be devastating," said François Batalingaya, U.N. Resident and Humanitarian Coordinator in Chad at the same briefing, describing the conditions for some 300,000 people stranded there with few aid services due to funding shortages.
The disease has not yet been confirmed in Chad, although a WHO spokesperson said that suspected cases had been reported in Geneina, Sudan which is just 10 km (6.2 miles) away. Sahbani also said that disease surveillance was low on the Libyan border and that it could possibly spread there.
Case fatality rates have fallen in recent weeks in and around the capital Khartoum thanks to an oral cholera vaccination campaign that started this month, Sahbani said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Alcohol linked to increased risk of pancreatic cancer: Study
Alcoholic beverages, particularly beer and spirits, may increase the risk of developing pancreatic cancer, according to a new study led by the UN World Health Organization. The research, which pooled data from nearly 2.5 million people across Asia, Australia, Europe and North America, revealed a 'modest but significant' link between alcohol consumption and pancreatic cancer risk, regardless of sex or smoking status. 'Alcohol consumption is a known carcinogen, but until now, the evidence linking it specifically to pancreatic cancer has been considered inconclusive,' said Pietro Ferrari, senior author of the study and head of the nutrition and metabolism branch at the World Health Organization International Agency for Research on Cancer. The study revealed that each additional 10 grams of alcohol consumed per day was associated with a three percent increase in pancreatic cancer risk. Additionally, women consuming 15-30 grams of alcohol daily, which equates to about one to two drinks, had a 12 percent higher risk. Men drinking 30-60 grams daily had a 15 percent increased risk, increasing to 36 percent for those consuming more than 60 grams. The study confirmed alcohol as an 'independent risk factor,' even after accounting for smoking. Ferrari emphasized that 'alcohol is often consumed in combination with tobacco,' but the elevated risk persists among non-smokers. Pancreatic cancer, a disease that impacts digestive enzyme production and blood sugar regulation, remains one of the deadliest cancers due to late-stage diagnoses. Although it ranks 12th in global cancer incidence, it accounts for 5 percent of all cancer-related deaths, according to the WHO. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 days ago
- Yahoo
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
By Bhanvi Satija (Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite. The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron and Scholar Rock. Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week. Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to preserve muscle will grow with the use of GLP-1 drugs for obesity, said TD Cowen analyst Tyler Van Buren. Doctors have raised concerns that patients may experience a decrease in overall strength due to muscle loss associated with Zepbound and Wegovy, while experts suggest that more muscle can help patients maintain long-term weight loss. Van Buren said that the first such treatment could launch by 2028, although regulatory challenges remain because these treatments must demonstrate additional health benefits to secure approval. "We believe quality of weight loss and lean mass preservation ... is far too important for long-term health outcomes to be ignored and that this will be figured out," Van Buren said. Some of the new drugs target the myostatin protein, which is associated with muscle growth, and are expected to see broader use due to their superior safety profile, capturing the majority of the market share, Van Buren said. Other drugs target activin, a protein with multiple biological functions. Van Buren said that activin-based drugs will be reserved for patients at higher risk of losing strength, forecasting sales of about $5 billion by 2035. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
2 days ago
- The Hill
New COVID variant causes ‘razor blade throat'
Patients and doctors say the latest COVID-19 variant spreading in the U.S. in some cases causes a sore throat so painful it has earned the nickname 'razor blade throat.' The 'Nimbus' variant, which is officially known as NB.1.8.1., is a descendant of the Omicron is currently being monitored by the World Health Organization. 'Your throat is so dry, so cracked, it's so painful, it's even hard to drink sometimes,' Muhammad Azam, a physician with Sharp Community Medical Group in California, told ABC 10. The variant was first identified in January. It has since been found around the globe, including in Canada and at least 13 states in the U.S. Apart from 'razor blade throat,' it causes symptoms similar to other Omicron variants of the virus, like cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting and loss of smell or taste, according to the Centers for Disease Control and Prevention. 'Sore throat has been a part of the spectrum of COVID from the beginning,' said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security. 'It is something that we know occurs just like it occurs with many other respiratory viruses.' Most cases of COVID-19 in the U.S. are still caused by the LP.8.1. strain, but the NB.1.8.1 variant is becoming increasingly prominent. According to CDC data, 38 percent of COVID cases stem from the LP.8.1 strain while 37 percent of COVID cases now stem from the 'Nimbus' variant. The agency notes on its website that, given the low number of virus sequences being reported, its precision is low. NB.1.8.1 does not appear to be any more of a global threat than other variants, according to the WHO. The organization also said that the existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization caused by the new variant. Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco, told ABC News that most COVID patients are reporting sore throat. 'I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum,' he said.
